Screening for Coxiella burnetii infection during pregnancy: Pros and cons according to the Wilson and Jungner criteria

Eurosurveillance

Volumn 17, Issue 3, 2012, Pages

  Munster, J M ^a,b   Steggerda, L M ^a   Leenders, A C ^c   Aarnoudse, J G ^b   Hak, E ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DOXYCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; COXIELLA BURNETII; DISEASE TRANSMISSION; HUMAN; IMMUNOFLUORESCENCE TEST; INCIDENCE; POLYMERASE CHAIN REACTION; PREGNANCY; Q FEVER; SCREENING; SEROLOGY; VACCINATION; WILSON AND JUNGNER CRITERIA;

EID: 84856259791     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gilbert GL. 1: Infections in pregnant women. Med J Aust. 2002;176(5):229-36.
2. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report on communicable diseases in Europe 2010. Stockholm: ECDC; 2010. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf.
3. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis. 2007;45(5):548-55.
4. Tissot-Dupont H, Vaillant V, Rey S, Raoult D. Role of sex, age, previous valve lesion and pregnancy in the clinical expression and outcome of Q fever after a large outbreak. Clin Infect Dis. 2007;44(2):232-7.
5. Wilson JMG, Jungner G. Principles and practice of screening for disease. World Health Organization public health papers. 1968;34. Geneva: World Health Organization; 1968. Available from: http://whqlibdoc.who.int/php/WHO_PHP_34.pdf.
6. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317-9.
7. Gilsdorf A, Kroh C, Grimm S, Jensen E, Wagner-Wiening C, Alpers K. Large Q fever outbreak due to sheep farming near residential areas, Germany, 2005. Epidemiol Infect. 2008;136(8):1084-7.
8. Roest HI, Tilburg JJ, Van der Hoek W, Vellema P, van Zijderveld FG, Klaassen CH, et al. The Q fever epidemic in The Netherlands: history, onset, response and reflection. Epidemiol Infect. 2011;139(1):1-12.
9. National Institute for Public Health and the Environment (RIVM). Q-koorts [Q fever]. Bilthoven: RIVM. [Accessed 27 Jun 2011]. Dutch. Available from: http://www.rivm.nl/Onderwerpen/Ziekten_Aandoeningen/Q/Q_koorts.
10. Van der Hoek W, Meekelenkamp JCE, Leenders ACAP, Wijers N, Notermans DW, Hukkelhoven CWPM. Antibodies against Coxiella burnetii and pregnancy outcome during the 2007-2008 Q fever outbreaks in The Netherlands. BMC Infect Dis. 2011;11:44.
11. Langley JM, Marrie TJ, Le Blanc JC, Almudevar A, Resch L, Raoult D. Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. Am J Obstet Gynecol. 2003;189(1):228-32.
12. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518-53.
13. Woude W, Dercksen DP. Abortion and stillbirth among dairy goats as a consequence of Coxiella burnetii. Tijdschr Diergeneeskd. 2007;132(23):908-11. Dutch.
14. Harris RJ, Storm PA, Lloyd A, Arens M, Marmion BP. Long-term persistence of Coxiella burnetii in the host after primary Q fever. Epidemiol Infect. 2000;124(3):543-9.
15. Sánchez J, Souriauy A, Buendía AJ, Arricau-Bouvery N, Martínez CM, Salinas J, et al. Experimental Coxiella burnetii infection in pregnant goats: a histopathological and immunohistochemical study. J Comp Pathol. 2006;135(2-3):108-15.
16. Stein A, Raoult D. Q fever during pregnancy: a public health problem in Southern France. Clin Infect Dis. 1998;27(3):592-6.
17. Fournier P, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol. 1998:36(7):1823-34.
18. Dupont HT, Thirion X, Raoult D. Q fever serology: cutoff determination for microimmunofluorescence. Clin Diagn Lab Immunol. 1994;1(2):189-96.
19. Jones JL, Krueger A, Schulkin J, Schantz PM. Toxoplasmosis prevention and testing in pregnancy, survey of obstetrician- gynaecologists. Zoonoses Public Health. 2010;57(1):27-33.
20. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608-14.
21. Forna F, McConnell M, Kitabire FN, Homsy J, Brooks JT, Mermin J, et al. Systematic review of the safety of trimethoprimsulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev. 2006;8(1);24-36.
22. Anthony S, Amelink-Verburg MP, Jacobusse GW, van der Pal-de Bruin KM. De Thuisbevalling in Nederland 1995-2002. Rapportage over de jaren 2001-2002 [Report on home delivery in the Netherlands 2001-2002]. Bilthoven: The Netherlands Perinatal Registry; June 2005. Dutch. Available from: http://www.perinatreg.nl/uploads/153/99/Rapportage_Thuisbevalling_2001-2002.pdf.
23. Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia's national Q fever vaccination program. Vaccine. 2009;27(14):2037-41.